Literature DB >> 2060142

Skeletal responsiveness to parathyroid hormone in healthy females: relationship to menopause and oestrogen replacement.

C Joborn1, S Ljunghall, K Larsson, E Lindh, T Naessén, L Wide, G Akerström, J Rastad.   

Abstract

In order to directly evaluate the role of parathyroid hormone (PTH) and its interaction with oestrogens for postmenopausal bone loss, studies were performed where synthetic human (1-38) PTH was infused s.c. over 24 h in 15 healthy females. Measurements were made of serum electrolytes, PTH and biochemical indices of bone turnover: serum osteocalcin and alkaline phosphatase and fasting urinary hydroxyproline and calcium. During the infusion of PTH there were significant increases of serum calcium (15%), fasting urinary calcium (55%) and hydroxyproline (80%) but a reduction of the serum osteocalcin concentrations (15%). There were significant relations between the calcaemic response and the increases of urinary calcium and hydroxyproline and the two latter were also closely related. There was, however, no correlation between the responses to PTH for the formative vs the resorptive indices. Postmenopausal women displayed greater increases of serum calcium and fasting urinary hydroxyproline indicating greater skeletal sensitivity to exogenous PTH. Following treatment with oestrogens the indices of skeletal responsiveness were reversed towards the premenopausal values. The findings demonstrate that during short-term infusion of PTH there is a dissociation between bone resorption and formation and, furthermore, that the menopause is associated with an enhanced skeletal sensitivity for PTH.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060142     DOI: 10.1111/j.1365-2265.1991.tb00302.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  11 in total

1.  Comparative Resistance to Teriparatide-Induced Bone Resorption With Denosumab or Alendronate.

Authors:  Joy N Tsai; Yuli Zhu; Katelyn Foley; Hang Lee; Sherri-Ann Burnett-Bowie; Robert M Neer; Benjamin Z Leder
Journal:  J Clin Endocrinol Metab       Date:  2015-05-01       Impact factor: 5.958

2.  Acute decline in serum sclerostin in response to PTH infusion in healthy men.

Authors:  Elaine W Yu; Ruchit Kumbhani; Erica Siwila-Sackman; Benjamin Z Leder
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

3.  Differential effects of dietary calcium augmentation and hormone replacement therapy on bone turnover and serum levels of calcitrophic hormones.

Authors:  J F Aloia; A Vaswani; J K Yeh; L Russo
Journal:  Osteoporos Int       Date:  1996       Impact factor: 4.507

4.  Serum osteocalcin and fracture susceptibility in elderly women.

Authors:  K Akesson; S Ljunghall; P Gärdsell; I Sernbo; K J Obrant
Journal:  Calcif Tissue Int       Date:  1993-08       Impact factor: 4.333

5.  Primary hyperparathyroidism: epidemiology, diagnosis and clinical picture.

Authors:  S Ljunghall; P Hellman; J Rastad; G Akerström
Journal:  World J Surg       Date:  1991 Nov-Dec       Impact factor: 3.352

6.  Effects of infusion of parathyroid hormone and primary hyperparathyroidism on formation and breakdown of type I collagen.

Authors:  H Brahm; O Ljunggren; K Larsson; E Lindh; S Ljunghall
Journal:  Calcif Tissue Int       Date:  1994-12       Impact factor: 4.333

7.  Does multiple gland disease in primary hyperparathyroidism correlate with age or sex?

Authors:  Denis Wirowski; Bernhard J Lammers; Peter Pohl; Katharina Schwarz; Peter E Goretzki
Journal:  Langenbecks Arch Surg       Date:  2009-06-17       Impact factor: 3.445

8.  Age- and sex-related incidence of surgically treated primary hyperparathyroidism.

Authors:  Barbra S Miller; Justin Dimick; Reid Wainess; Richard E Burney
Journal:  World J Surg       Date:  2008-05       Impact factor: 3.352

9.  Renal stone disease, elevated iPTH level and normocalcemia.

Authors:  Nada B Dimkovic; Abdul Aziz Wallele; Dimitrios G Oreopoulos
Journal:  Int Urol Nephrol       Date:  2002       Impact factor: 2.370

10.  Effects of teriparatide treatment and discontinuation in postmenopausal women and eugonadal men with osteoporosis.

Authors:  Benjamin Z Leder; Robert M Neer; Jason J Wyland; Hang W Lee; Sherri-Ann M Burnett-Bowie; Joel S Finkelstein
Journal:  J Clin Endocrinol Metab       Date:  2009-05-12       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.